Marshall Wace, LLP Akebia Therapeutics, Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.86 - $1.63 $667,537 - $1.27 Million	-776,206 Reduced 75.86%	247,069 $252,000
Q1 2024 May 15, 2024	BUY	$1.27 - $2.24 $1.3 Million - $2.29 Million	1,023,275 New	1,023,275 $1.87 Million
Q3 2022 Nov 14, 2022	BUY	$0.3 - $0.46 $94,294 - $144,585	314,316 New	314,316 $101,000
Q1 2022 May 16, 2022	SELL	$0.72 - $2.93 $3.22 Million - $13.1 Million	-4,475,138 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.26 - $3.34 $5.64 Million - $8.33 Million	-2,493,673 Reduced 35.78%	4,475,138 $10.1 Million
Q3 2021 Nov 15, 2021	BUY	$2.35 - $3.88 $6.72 Million - $11.1 Million	2,859,222 Added 69.57%	6,968,811 $20.1 Million
Q2 2021 Aug 13, 2021	BUY	$2.83 - $4.2 $11.6 Million - $17.3 Million	4,109,589 New	4,109,589 $15.6 Million
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $85,643 - $145,824	-38,578 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$2.39 - $13.08 $770,509 - $4.22 Million	-322,389 Reduced 89.31%	38,578 $97,000
Q2 2020 Aug 13, 2020	BUY	$6.67 - $13.58 $2.41 Million - $4.9 Million	360,967 New	360,967 $4.9 Million
Q2 2019 Aug 14, 2019	SELL	$4.1 - $8.05 $152,778 - $299,967	-37,263 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$5.41 - $8.73 $2.69 Million - $4.34 Million	-496,678 Reduced 93.02%	37,263 $305,000
Q4 2018 Feb 14, 2019	SELL	$5.39 - $9.15 $27,612 - $46,875	-5,123 Reduced 0.95%	533,941 $2.95 Million
Q3 2018 Nov 14, 2018	SELL	$7.44 - $10.65 $1,450 - $2,076	-195 Reduced 0.04%	539,064 $4.76 Million
Q2 2018 Aug 14, 2018	BUY	$9.15 - $11.34 $2.79 Million - $3.45 Million	304,490 Added 129.7%	539,259 $5.38 Million
Q1 2018 May 15, 2018	BUY	$9.53 - $15.68 $291,360 - $479,384	30,573 Added 14.97%	234,769 $2.24 Million
Q4 2017 Feb 14, 2018	BUY	$14.24 - $19.59 $1.63 Million - $2.24 Million	114,349 Added 127.27%	204,196 $3.04 Million
Q3 2017 Nov 13, 2017	BUY	$13.06 - $19.67 $1.17 Million - $1.77 Million	89,847	89,847 $1.8 Million

Others Institutions Holding AKBA

# of Institutions

120

Shares Held

54.8M

Call Options Held

291K

Put Options Held

179K

Black Rock Inc. New York, NY

11.6M
Shares

$20.5 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.1M
Shares

$17.7 Million
0.0% of portfolio
Satter Management Co., L.P.

5.75M
Shares

$10.1 Million
13.23% of portfolio
Geode Capital Management, LLC Boston, MA

4.75M
Shares

$8.37 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

3.72M
Shares

$6.54 Million
0.01% of portfolio

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account